Evidence map›Paper›PMID 41536779›Full record

ArticleBlood neoplasia2026

Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial.

Giovanni Martinelli, Scott R Solomon, Sudipto Mukherjee, Armando Santoro, Stephen A Strickland, Susana Vives, Farhad Ravandi, Roland B Walter, Rachel J Cook, Ewa Lech-Maranda and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Giovanni MartinelliDepartment of Medical and Surgical Sciences, Seràgnoli Institute, University of Bologna, Bologna, Italy.
Scott R SolomonBlood and Marrow Transplant Matched Unrelated Donor Program, Northside Hospital Cancer Institute, Atlanta, GA.
Sudipto MukherjeeDepartment of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH.
Armando SantoroDepartment of Biomedical Sciences, Istituto Clinico Humanitas, Milan, Italy.
Stephen A StricklandVanderbilt-Ingram Cancer Center, Nashville, TN.
Susana VivesDepartment of Hematology, Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras, Barcelona, Spain.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Roland B WalterTranslantional Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
Rachel J CookCenter for Hematologic Malignancies, Oregon Health & Science University, Portland, OR.
Ewa Lech-MarandaInstitute of Haematology and Transfusion Medicine, Warsaw, Poland.
Maria CalbachoHematology and Hemotherapy, Hospital Universitario 12 de Octubre, Madrid, Spain.
Agnieszka WierzbowskaMedical University of Lodz and Provincial Multi-specialized Oncology and Trauma Center, Lodz, Poland.
Giovanni MarconiDepartment of Medical and Surgical Sciences, Ospedale S. Maria delle Croci, University of Bologna, Ravenna, Italy.
Evelyn Acuña-CruzDepartment of Hematology and Hemotherapy, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Isabel Cano-FerriDepartment of Hematology and Hemotherapy, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Francesco BertoliniLaboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Tomasz RzymskiRyvu Therapeutics, Krakow, Poland.
Alessandro PaoliMenarini Group, Pomezia, Italy.
Giovanni Marino MerloMenarini Group, Florence, Italy.
Faten Koraichi AuriolMenarini Group, Paris, France.
Sonia ZicariMenarini Group, Pomezia, Italy.
Antonio GalleuMenarini Group, Florence, Italy.
Ira GuptaMenarini Group, New York, NY.
Pau MontesinosDepartment of Hematology and Hemotherapy, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is an aggressive hematopoietic cancer with poor survival outcomes. Despite improvements with recent FMS-like tyrosine kinase 3 (FLT3) inhibitors, resistance is common, and responses are short. Dapolsertib (MEN1703) is a novel, first-in-class dual inhibitor of PIM (proviral integration site for Moloney murine leukemia virus) and FLT3 kinases, with activity in both

Identifiers

PMID41536779
PMCPMC12796535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.